Ann Arbor, MI, United States of America

Ingo Janser

This inventor holds 1 USPTO granted patent. Top assignee: Reata Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ingo Janser. Retrieved from https://idiyas.com/inventor/ingo-janser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ingo Janser and His Patent in Pharmaceutical Innovation.

Introduction

Ingo Janser is an inventor associated with Ann Arbor, Michigan, and Reata Pharmaceuticals, Inc. His patent work concerns synthetic triterpenoids and their potential pharmaceutical applications.

Latest Patents

The supplied information identifies one patent associated with Janser: “Synthetic triterpenoids with nitrogen-based substituents at C-17 and methods of use thereof.” The patent describes compounds, including compounds represented by formulas (I) and (II), and pharmaceutical compositions containing them. It also discusses their potential use as antioxidant inflammation modulators and methods for treating diseases and disorders associated with inflammation and cancer. Janser is credited with 1 patent.

Career Highlights

Janser’s listed work connects him with Reata Pharmaceuticals, Inc., a company focused on pharmaceutical research and development. The patent reflects an area of innovation involving compounds intended to address inflammation and cancer-related conditions.

Collaborations

The supplied information lists Christopher F. Bender and Ha Do as Janser’s coworkers. Their names provide context for the professional network associated with his work.

Conclusion

Ingo Janser’s identified patent documents research into synthetic triterpenoids and their potential therapeutic uses, highlighting his contribution to pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…